Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder (Q37055322)

18 August 2017

1 reference

title

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder (English)

1 reference

18 August 2017

Richard C Shelton

1 reference

18 August 2017

George I Papakostas

series ordinal

1 reference

18 August 2017

language of work or name

English

0 references

publication date

8 January 2008

1 reference

Acta Psychiatrica Scandinavica

18 August 2017

published in

1 reference

18 August 2017

volume

117

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

253-259

1 reference

A SELF-RATING DEPRESSION SCALE

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

The Mechanism of Action of Novel Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Clozapine: new research on efficacy and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Aripiprazole as an adjunctive treatment for refractory major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.01130.X

10.1111/J.1600-0447.2007.01130.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference